# US 2016/0250254 A1 · Methods of reducing doses of erythropoietin stimulating agents in hyporesponsive patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250254 A1
- Document ID: US20160250254A1
- Status: Published application
- Kind: A1
- Application number: 15/033,846
- Filed: 2014-11-04
- Published: 2016-09-01
- Earliest claimed: 2013-11-05
- Assignees: Rockwell Medical, Inc.
- Applicants: Rockwell Medical, Inc.
- Inventors: Ajay Gupta; Raumond Pratt; Vivian H. Lin; Carrue Guss
- Web page: https://patentgrep.com/patent/US20160250254A1

## CPC

- A61K 33/26: Iron; Compounds thereof
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 33/42: Phosphorus; Compounds thereof
- A61K 38/1816: {Erythropoietin [EPO]}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61M 1/287: {Dialysates therefor}
- A61P 7/06: Antianaemics
- A61P 7/08: Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock (artificial tears A61P27/04)
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The invention provides for methods of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agents (ESA) comprising administering soluble ferric triphosphate (SFP) composition and administering a dose of ESA that is significantly reduced compared to the dose of ESA required by a dialysis patient that is hyporesponsive to ESA that has not received SFP.

## Claims

### Claim 1

A method of treating a dialysis patient that is hyporesponsive to erythropoietin stimulating agent (ESA) comprising:
(a) administering to the patient soluble a ferric pyrophosphate composition (SFP), and
(b) administering to the patient a dose of ESA that is at least 50% less than the dose of ESA required by dialysis patients that are hyporesponsive to ESA and that have not received SFP.

### Claim 2 (depends on 1)

The method of claim 1 wherein the dose of SFP is administered via a parenteral route selected from the group consisting of intramuscular, subcutaneous, intravenous, intradermal, transdermal, transbuccal, sublingual, intra-peritoneal or by dialytic transfer via the hemodialysis solutions or peritoneal dialysis solutions.

### Claim 3 (depends on 1)

The method of claim 1 wherein the dose of SFP is administered orally.

### Claim 4

The method of any of the preceding claims wherein the dose of SFP is administered in conjunction with other drugs such as heparin or parenteral nutrition admixtures or dialysis solutions.

### Claim 5

The method of any of the preceding claims, wherein the dose of SFP increases or maintains the hemoglobin level of the patient at 9 g/dL or greater.

### Claim 6 (depends on 1, 2, 4, 5)

The method of any one of claims 1, 2, 4 and 5, wherein the dose of SFP is administered via hemodialysate at a dose ranging from 90 μg Fe/L dialysate to 120 μg Fe/L dialysate.

### Claim 7 (depends on 6)

The method of claim 6, wherein the SFP is administered via hemodialysate at a dose of 110 μg Fe/L dialysate.

### Claim 8 (depends on 1, 2, 4, 5)

The method of any one of claims 1, 2, 4 and 5, wherein the dose of SFP is administered via infusion or intravenous injection at a dose ranging from 2.4 mg to 48 mg iron per day at a rate of 0.1 to 2 mg iron per hour.

### Claim 9 (depends on 1, 2, 4, 5)

The method of any one of claims 1, 2, 4 and 5 wherein the dose of SFP is administered into the circulation at a dose ranging 2.4 mg to 48 mg iron per day at a rate of 0.1 to 2 mg iron per hour.

### Claim 10

The method of any one of the preceding claims, wherein the dose of ESA administered to the patient after SFP administration is at least 70% less than the dose of ESA administered prior to SFP administration.

### Claim 11

The method of any of the preceding claims wherein the SFP comprises iron chelated with citrate and pyrophosphate.

### Claim 12

The method of any of the preceding claims wherein the SFP comprises iron in an amount of 7% to 11% by weight, citrate in an amount of at least 14% by weight, and pyrophosphate in an amount of at least 10% by weight.

### Claim 13

The method of any of the preceding claims wherein the SFP is administered via dialysate and the dose of intravenously administered iron after SFP administration is at least 10% less than the dose of intravenously administered iron prior to SFP administration.

### Claim 14

The method of any of the preceding claims wherein the patient is suffering from chronic kidney disease, optionally stage III, IV or V.

### Claim 15

The method of any of the preceding claims wherein the patient is suffering from stage IV or V chronic kidney disease.

### Claim 16

The method of any of the preceding claims wherein the patient is undergoing hemodialysis.

### Claim 17

The method of any of the preceding claims wherein the patient is suffering from anemia of inflammation.

### Claim 18

The method of any of the preceding claims wherein the patient is suffering from infection, optionally chronic infection.

### Claim 19

The method of any one of the preceding claims wherein the patient is suffering from cancer, heart failure, autoimmune disease, sickle cell disease, thalassemia, blood loss, transfusion reaction, diabetes, vitamin B12 deficiency, collagen vascular disease, thrombocytopenic purpura, Celiac disease, endocrine deficiency state, hypothyroidism, Addison's disease, Crohn's Disease, systemic lupus erythematosis, rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, immune disorders, eosinophilic fasciitis, hypoimmunoglobulinemia, thrymoma/thymic carcinoma, graft vs. host disease, preleukemia, Nonhematologic syndrome, Felty syndrome, hemolytic uremic syndrome, myelodysplasic syndrome, nocturnal paroxysmal hemoglobinuria, osteomyelofibrosis, pancytopenia, pure red-cell aplasia, Schoenlein-Henoch purpura, malaria, protein starvation, menorrhagia, systemic sclerosis, liver cirrhosis, hypometabolic states, congestive heart failure, chronic infection, HIV/AIDS, tuberculosis, osteomyelitis, hepatitis B, hepatitis C, Epstein-bar virus, parvovirus, T cell leukemia virus, bacterial overgrowth syndrome, red cell membrane disorder, hereditary spherocytosis, hereditary elliptocytosis, red cell enzyme defects, hypersplenism, immune hemolysis or paroxysmal nocturnal hemoglobinuria.

### Claim 20

The method of any one of the preceding claims wherein dose of SFP is administered during hemodialysis within the hemodialysate solution.

### Claim 21

The method of any of the preceding claims wherein SFP is administered during peritoneal dialysis within the peritoneal dialysis solution.

### Claim 22

The method of any one of the preceding claims wherein SFP is administered with parenteral nutrition within parenteral nutrition admixture.

### Claim 23

The method of any one of the preceding claims wherein SFP is administered at a therapeutically effective dose that i) increases at least one marker of iron status selected from the group consisting of serum iron, transferrin saturation, reticulocyte hemoglobin, serum ferritin, reticulocyte count, and whole blood hemoglobin and ii) decreases the dose of ESA required to achieve or maintain target hemoglobin levels, or the need for transfusion of whole blood, packed red blood cell or blood substitutes.

### Claim 24 (depends on 23)

The method of claim 23, wherein the patient is suffering from non-anemic iron deficiency and administration of the therapeutically effective dose of SFP reduces fatigue, increases physical and cognitive ability, or improves exercise tolerance in the patient.

### Claim 25

The method of any one of the preceding claims wherein SFP is administered in a therapeutically effective dose that will reduce or abolish the clinical manifestations of restless leg syndrome associated with iron
